

CSD/BSE&NSE/2024-25 March 25, 2025

To The Manager Department of Corporate Services BSE Limited 25th Floor, P. J. Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Analyst/Institutional Investor Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the management of the Company will be attending the below mentioned roadshows:

Date	Roadshow	Location	Group/One-one
March 31 – April 01, 2025	B&K	Hong Kong	Group/One-One
April 2 – April 3, 2025	Macquarie	Singapore	Group/One-One

No unpublished price-sensitive information will be shared during this interaction.

Note: The schedule of the aforesaid meetings is subject to change. The change may happen due to exigencies on the part of Analyst/ Institutional Investor/ Company.

You are requested to take this information on records.

Thanking You.

Yours faithfully, For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-
821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999Corporate Office: # 202, A-Wing, Galaxy Towers, Plot
No.1, Hyderabad Knowledge City, TSIIC, Raidurg,
Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311Email: info@suvenpharm.com I Website: www.suvenpharm.com I CIN: L24299MH2018PLC422236